Register for our free email digests:
Number To Know
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
SEK29 was the final price at which Bonesupport's shares were set in the Swedish company's initial public offering on the Nasdaq Stockholm.
Stryker has agreed to pay $11.75 per share in cash to acquire Canadian imaging technology firm Novadaq. The purchase price is almost twice Novadaq's closing share price on June 16, the last trading day before the deal was announced.
40% is the approximately how much IVD-related sales will contribute to PerkinElmer's total revenue once the company completes its $1.3bn acquisition of EUROIMMUN, a privately held European specialist in autoimmune, infectious disease and allergy testing.
Patients implanted with Corlife's decellularized human pulmonary valve, Espoir PV, in a European trial have shown 99% freedom from explantation, according to preliminary findings.
US FDA cleared 299 510(k)s in May, the most coming out of the agency in one month since December 2014.
22.4% is the increase in number of medtech patents filings from the UK between 2015 and 2016. This underlines the UK's reputation as one of the leading European innovators in life sciences, as the country's capital plays host to London Tech Week between June 12-16.
The Australian Therapeutic Goods Administration receive around 300 applications each year for medical devices to be audited and registered for sale in the country. But the introduction of Australian-designated notified bodies should help alleviate some of this burden.
10 is the number of non-US approvals recorded in May, by Medtech Insight's product approvals table.
16 is the number of years Jeff Immelt will have served as GE's head honcho before retiring. His successor is president and CEO of GE Healthcare John Flannery.
There are around 25,000 pharmacies in Turkey that have been permitted, under a new agreement with the public health care payer, to sell medical devices that would others be sold exclusively by the country's specialist medical device retailers.
The Sentinel, which became the first and only embolic removal device cleared by the US FDA for use on patients undergoing transcatheter aortic valve replacement, is said to intercept visible debris in 99% of cases.
The 28 medtech venture capital deals with disclosed financials in May totaled about $935m. The total was down from a peak in March, but higher than any other month this year and ahead of May totals in the previous four years.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.